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The origin of metastatic adenocarcinoma lesions can sometimes be difﬁcult to diagnose. The objectives of our study were to
establish the cytokeratin staining pattern of primary and metastatic lung and colorectal adenocarcinomas, and to determine if
this helps to identify the site of origin of metastatic lesions. We reviewed a total of 102 tissue samples from patients in our
tumour registry, with either primary or metastatic lung or colorectal adenocarcinoma. Tissue sections were stained for
cytokeratin 7 and 20 and read as positive or negative for staining. Clinical and radiologic information was reviewed from
computerised charts. The cytokeratin 7+/cytokeratin 207 pattern characterised 96% (29 out of 30) of primary and 95% (21
out of 22) of metastatic lung adenocarcinomas. All the primary (26), and 88% (21 out of 24) of metastatic colorectal
adenocarcinomas stained cytokeratin 77/cytokeratin 20+. Samples from a variety of metastatic sites were evaluated for
cytokeratin 7 and 20 staining. Out of the 102 samples, in 95% (97 out of 102) of the cases, the cytokeratin 7 and cytokeratin
20 staining pattern characterised and differentiated between lung and colorectal adenocarcinoma. Primary and metastatic lung
adenocarcinomas show a cytokeratin 7+/cytokeratin 207 staining pattern, while colorectal adenocarcinomas stain cytokeratin
77/cytokeratin 20+. Cytokeratin staining is helpful in the diagnostic differentiation of metastatic lesions from these two
common primaries, and assists in determining the site of origin of metastatic lesions.
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In patients who present with metastatic disease, determining the
primary site of origin may have a major impact on prognosis
and therapy. However, in spite of clinical, radiographic, and
routine histologic studies, the primary site remains uncertain in
approximately 3–15% of cases (Abbruzzese et al, 1995; Hammar,
1998). A signiﬁcant proportion of these cases are adenocarcinomas,
and they present a challenge for the pathologist and the oncologist
alike.
Cytokeratins are intermediate ﬁlament proteins present in
epithelial cells. They are expressed in a tissue-speciﬁc manner
in normal organs and the tumours that arise from them. Mono-
clonal antibodies have been established against several of the
cytokeratin polypeptides and are used to evaluate the pattern
of cytokeratin expression in cells of epithelial origin. Chu et al
(2000) studied the expression of two of the low molecular weight
cytokeratin subtypes, CK7 and CK20, in 435 cases of epithelial
neoplasms. They observed CK7 expression in the majority of
lung, breast, endometrium, ovary, cervix, salivary gland, thyroid
cancers, cholangiocarcinoma, and adenocarcinoma of the
pancreas. In contrast, CK20 staining was seen in all colorectal
adenocarcinomas and in the majority of gastric, pancreatic, and
Merkel cell tumours. Prostate, kidney, and adrenocortical carci-
nomas as well as sarcomas, carcinoids, hepatocellular
carcinomas and thymomas were negative for both CK7 and
CK20 staining, while a large proportion of pancreatic and
cholangiocarcinomas as well as some bladder and gastric tumours
expressed both CK7 and CK20.
Based on the differential pattern of cytokeratin staining reported
in the literature, we decided to evaluate the cytokeratin expression
in tissue samples of lung and colorectal adenocarcinomas, obtained
from our patient population. The objectives of our study were to:
(i) establish the cytokeratin staining pattern of primary lung and
colorectal adenocarcinomas; (ii) correlate the expression of the
primary with that of the metastatic lesion; and (iii) determine if
evaluating the cytokeratin 7 and 20 staining helps to identify the
primary site of origin of metastatic lesions.
MATERIALS AND METHODS
One hundred and two samples from patients with primary or
metastatic lung or colorectal adenocarcinoma were identiﬁed from
the Veteran’s Administration (VA) Connecticut Cancer Center
Tumor Registry (1995–2001) and evaluated for cytokeratin stain-
ing. All patients were male, representing a relatively homogenous
population with regards to age and risk factors for lung cancer,
namely smoking. All tumour samples were adenocarcinomas, with
most being moderately to poorly differentiated. The sites of meta-
static disease biopsied in patients with lung cancer included the
pleura, pleural effusion, soft tissue, bone, small bowel, adrenal
gland, bone marrow and liver. Metastatic colorectal cancer deposits
that were sampled included deposits in the lung, liver, lymph
nodes, chin and small bowel. Clinical information was reviewed
from computerised charts.
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cut at 5 microns. Sections were then mounted on positive charged
slides Shandon catalogue number 6776214, Shandon Inc., Pitts-
burgh, PA, USA and placed in a laboratory incubator at 608C,
for 40 min. Slides were cooled and re-hydrated with three changes
of Histosolve (Shandon catalogue number 6764508) for 5 min
each, two changes of absolute ethanol for 5 min each, one change
of 95% ethanol for 5 min, and then transferred to tap water. Slides
were then ‘quenched’ in a mixture of methanol and 3% hydrogen
peroxide (97 ml methanol with 3 ml of 3% hydrogen peroxide
added) for 30 min.
Slides were then placed on an automated immunohistochemis-
try stainer (Ventana ES, Ventana Medical Systems, Tucson, AZ,
USA) with the following reagents: Mouse anti-human cytokeratin
7 monoclonal antibody (Dako catalogue number M 7018, Dako
Corporation, Carpinteria, CA, USA), 1:200 dilution using Venta-
na antibody diluent (catalogue number 251-018) for 34 min;
mouse anti-human cytokeratin 20 monoclonal antibody (Dako
catalogue number M 7019), 1:10 dilution using Ventana antibody
diluent (catalogue number 251-018) for 34 min. Subsequently, the
slides were processed with a DAB detection kit (Ventana catalogue
number 250-001) and counterstained using haematoxylin (Venta-
na catalogue number 250-2021) for 8 min, followed by immersion
in bluing reagent (Ventana catalogue number 250-2037) for
4 min.
Slides were removed from the stainer and washed with tap water
for 10 min. They were ﬁrst placed in 95% ethanol and then in
absolute ethanol for 5 min each, followed by four changes of
Histosolve for 5 min each. They were subsequently coverslipped
using a synthetic mounting media (Permount, Fisher catalogue
number SP-15-100, Fisher Healthcare, Houston, TX, USA).
Positive and negative controls were used as a basis for scoring
the sample slides. Immunostaining was evaluated semiquantita-
tively by estimating the number of stained cells. Samples with
over 5% of tumour cells showing CK staining were considered
positive (Wauters et al, 1995). At least two reviewers (T Ciesielski
and S Kummar) reviewed all slides.
RESULTS
A total of 102 samples of adenocarcinoma were identiﬁed from our
tumour registry and evaluated for cytokeratin expression using
cytokeratin 7 and 20 immunostains. Cancer cells were identiﬁed
morphologically and assessed for staining. Routine background
staining for CK7, but not for CK20, was observed for normal
mesothelial and alveolar cells in all lung biopsy slides, as has been
previously described in the literature. Normal colonic mucosa, as
well as benign polyps in the colon, were consistently strongly posi-
tive for CK20 staining. No background staining of normal
colorectal mucosa with CK7 was observed.
Primary lung and colorectal adenocarcinoma
In the initial phase of the study, the pattern of cytokeratin staining
for primary lung and colorectal adenocarcinoma was evaluated. A
total of 30 primary lung and 26 primary colorectal lesions were
studied. All primary lung lesions were CK7+, and 29 of these were
CK207 (Figure 1). In one case, focal CK20 staining of some of the
adenocarcinoma cells was observed. This patient was found to have
two tubular adenomas, with no evidence of a malignant lesion, on
a surveillance colonoscopy, 8 months prior to his lung surgery. All
the primary colon lesions (26) were CK77/CK20+ (Figure 2).
Overall, the CK7+/CK207 staining pattern was observed for
96% of primary lung adenocarcinoma lesions, while 100% of the
colorectal cancers showed the CK77/CK20+ staining pattern
(Tables 1 and 2). We did not ﬁnd consistent differences in the
staining intensity or per cent positive cells based on grade of the
tumour.
Patients with metastatic disease and/or recurrent disease
Patients with advanced metastatic adenocarcinoma and
radiologic evidence of a lung mass The metastatic site, and
not the radiologically apparent lung mass, was biopsied and a total
of 22 samples were studied. These included sites involving the
pleura, pleural effusion, soft tissue, bone, small bowel, adrenal
gland, bone marrow and liver. Ninety-ﬁve per cent of the samples
stained CK7+/CK207, consistent with a lung primary. No consis-
tent difference in staining pattern was observed for the different
metastatic sites. One case, involving the rib, stained negative for
both CK7 and CK20. The corresponding lung primary stained
positive for CK7, and negative for CK20. The other three samples
of metastatic lung cancer involving the bone, stained consistently
CK7+/CK207. In ﬁve cases, the metastatic site was biopsied prior
to the radiologic imaging of the chest, thus, helping to guide
further diagnostic evaluation (Table 1).
Patients with a known history of colorectal cancer, who
subsequently presented with metastatic adenocarcinoma A
total of 24 sites of recurrence/metastasis were biopsied and evalu-
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Figure 1 CK20 (A) and CK7 (B) immunostaining of primary lung ade-
nocarcinoma. CK20 (C) and CK7 (D) immunostain of metastatic lung ade-
nocarcinoma to the liver. Most of the tumour cells in both the primary and
the metastatic lesion show strong cytoplasmic staining with CK7 and nega-
tive staining with CK20 (original magniﬁcation 2006).
Figure 2 CK20 (A) and CK7 (B) immunostaining of primary colon ade-
nocarcinoma. CK20 (C) and CK7 (D) immunostain of metastatic colon
cancer to liver. There is focal strong cytoplasmic staining for CK20 in both
the primary and the metastatic lesion and negative staining with CK7 (ori-
ginal magniﬁcation 2006).
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included deposits in the lung, liver, lymph nodes, chin and small
bowel. Twenty-one (88%) samples revealed the CK77/CK20+
staining pattern (Figure 2). In six cases, cytokeratin staining of
the original colon tumour was also obtained, and stained CK77/
20+. Of the three cases that did not show the CK77/CK20+, in
one case the lung lesion was CK7+/CK207, consistent with a
second primary, arising in the lung. In the second case, the lung
biopsy stained negative for both CK7 and CK20. In this patient,
the primary colon tumour was CK77/CK20+, but the CK20 stain-
ing was focal. In the third case, the patient had a small bowel mass,
felt to be a metastasis from the known colorectal primary. Biopsy
of this mass stained positive for both CK7 and CK20.
Overall 102 samples were tested, and in 95% of the cases, the
CK7/CK20 staining pattern characterised and differentiated
between lung and colorectal adenocarcinoma.
DISCUSSION
There may be both prognostic and therapeutic information in
determining the site of origin of metastatic lesions. Our VA patient
population represents a relatively homogenous group of patients
with regard to age and sex, as well as their risk factors for both
lung and colorectal cancers. As a result, in patients who present
with metastatic adenocarcinoma, it is important to determine
whether the primary arose in the lung vs the colon.
Cytokeratins, a family of over 20 polypeptides, are markers of
epitheloid differentiation. The various cytokeratin subtypes are
expressed in a tissue-speciﬁc manner on cells of epithelial origin.
Adenocarcinomas of the lung have been reported to be CK7+,
while colon cancers are positive for CK20 staining (Wang et al,
1995; Rubin et al, 2001). Carcinoembryonic antigen (CEA) expres-
sion can also be used to evaluate colon adenocarcinoma lesions
(Lagendijk et al, 1998, 1999). However, primary lung cancer also
commonly stains positive for CEA, making the differentiation
between colon and lung primaries difﬁcult based on CEA expres-
sion alone (Raab et al, 1993). In the study presented herein, we
decided to evaluate the cytokeratin staining pattern of adenocarci-
noma samples from patients with primary and metastatic lung and
colorectal cancer. We wanted to determine if both the primary and
metastatic lesions stain consistently for CK7 and CK20, and
whether this aids in the diagnosis of the primary site of origin of
the metastatic lesions.
First, we established the CK7 and CK20 staining pattern of
primary lung and colorectal adenocarcinomas. Ninety-six per cent
of the primary lung lesions were CK7+/CK207, while 100% of
colorectal primaries stained CK77/CK20+. No differences were
observed in the staining pattern of right- vs left-sided colon lesions
or rectal primaries. There also was no signiﬁcant inter-observer
difference, although the study did not set out to establish the
reproducibility of CK staining.
Based on the above results, we decided to evaluate the staining
pattern of metastatic adenocarcinoma lesions at a variety of sites
from patients with either evidence of a dominant lung mass by
radiologic studies or known history of colorectal cancer. The
CK7+/CK207 pattern was observed for 95% of metastatic lesions
biopsied in patients with primary lung cancer. One sample
obtained from the rib, in a patient with a lung mass, stained nega-
tive for both cytokeratin 7 and 20. The primary lung tumour from
this patient showed strong staining with CK7, and was negative for
CK20. The lack of staining in the rib lesion could be due to
sampling error, as the amount of tumour tissue in the biopsy
specimen was small. We had three more cases of lung cancer meta-
static to bone, two involving the ribs and one in the femur. All
three showed strong and consistent staining with CK7. In patients
with a prior history of colorectal cancer, 88% of the samples
showed the characteristic CK77/20+ staining pattern, consistent
with metastasis from the known cancer. Thus, in our study we
found a consistent pattern for both the primary and metastatic
lesions, with no evidence of loss of cytokeratin staining in synchro-
nous or metachronous metastatic lesions. Loy and Calaluce (1994)
evaluated the cytokeratin 7 and 20 staining patterns of 50 meta-
static lung or colon adenocarcinoma samples. They reported that
83% of metastatic lung lesions showed CK7+/CK207 staining,
while 69% of metastatic colorectal lesions retained the typical
CK77/CK20+ staining pattern. Unlike in our series however, in
their group, none of the metastatic lung lesions and only two of
the colorectal metastatic deposits were in the liver.
Liver is a common site of metastasis, making the diagnosis of
primary site of origin difﬁcult. In a large autopsy series of adeno-
carcinomas metastatic to the liver, reported by Tot (1999), staining
for both CK7 and CK20 was evaluated. The CK77/CK20+ pattern
was observed for 17 of the 21 cases of colorectal adenocarcinoma.
However, no cases of primary lung adenocarcinoma were included
in this series. We identiﬁed and evaluated eight samples from liver
biopsies representing metastatic adenocarcinoma in our study
population. In ﬁve of the cases, the cytokeratin staining pattern
was CK7+/CK207. Subsequent diagnostic imaging studies revealed
the presence of a dominant lung mass, consistent with primary
lung cancer. In the other three cases, the patients had history of
colon cancer and subsequently presented with liver masses. Liver
biopsy samples in all these cases stained CK77/CK20+, consistent
with metastatic colorectal cancer.
Patients with history of colorectal cancer, who present with an
isolated adenocarcinoma lesion without evidence of other sites of
metastasis, raise concerns regarding whether this represents a
second primary vs metastasis from the known colorectal cancer.
This distinction carries obvious diagnostic and therapeutic implica-
tions. In this study, we identiﬁed patients with a history of
colorectal cancer, who subsequently developed a solitary adenocar-
cinoma lesion, without evidence of widespread metastasis by
computed tomography (CT). We reviewed four cases, three had
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Table 1 Cytokeratin staining of lung adenocarcinomas
CK 7+/207 CK 77/20+ CK 7+/20+ CK 77/207
Primary (n=30) 29 (96)* 0 1 (4) 0
Metastases (n=22) 21 (95) 0 0 1 (5)
Liver (5) 5 0 0 0
Bone (4) 3 (75) 0 0 1 (25)
Soft tissue (3) 3 0 0 0
Lymph nodes (4) 4 0 0 0
Pleural ﬂuid (2) 2 0 0 0
Pleura (1) 1 0 0 0
Adrenal gland (1) 1 0 0 0
Bone marrow (1) 1 0 0 0
Small bowel (1) 1 0 0 0
*=case number and (%).
Table 2 Cytokeratin staining of colorectal adenocarcinomas
CK 7+/207 CK 77/20+ CK 7+/20+ CK 77/207
Primary (n=26) 0 26 (100)* 0 0
Metastases (n=24) 1 (4) 21 (88) 1 (4) 1 (4)
Lymph node (11) 0 11 0 0
Lung (5) 1 (20) 3 (60) 0 1 (20)
Liver (3) 0 3 0 0
Small bowel (1) 0 0 1 0
Chin (1) 0 1 0 0
Fat nodule (1) 0 1 0 0
Peritoneum (1) 0 1 0 0
Bone (1) 0 1 0 0
*=case number and (%).
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the chin. Two of the lung lesions and the lesion in the chin showed
a staining pattern consistent with primary lung adenocarcinoma, a
second primary. Thus, cytokeratin staining of the metastatic lesion
provided important information regarding site of origin. Tan et al
(1998) reported a series of 10 cases with lung adenocarcinomas,
and nine cases of colon adenocarcinoma metastatic to the lung.
Biopsies from all 10 patients with lung primaries stained CK7+/
CK207, while all metastatic lesions from the colon were CK77/
CK20+ (Tan et al, 1998).
A large variety of sites were evaluated and showed adequate
staining. One of the main advantages of using cytokeratin staining
is the ability to obtain reliable staining, even when a small amount
of tissue is available, as in the case of cytology specimens. Harla-
mert et al (1998) reported a series of 21 cytology samples from
primary lung adenocarcinomas. All samples stained CK7+, with
an average of 480% of cells showing strong cytoplasmic staining.
In the present series, both solid (lung, liver and rectum) and ﬂuid
cytology (pleural ﬂuid) samples were tested and showed strong
staining for either CK7 or CK20. Moreover, repeated sampling
and testing in a patient with malignant pleural effusion consistently
showed the CK7+/CK20- staining pattern.
One of the drawbacks of cytokeratin staining is that tumours
may stain for both CK7 and CK20. In our study population, while
most tumours stained positive for either CK7 or CK20, there was
one case (4%) of primary lung cancer and one case (4%) of meta-
static deposit in the small bowel from a known colorectal cancer,
that expressed both CK7 and CK20. The ratio of CK7/CK20 stain-
ing for lung biopsy was 10–20/1, while for small bowel it was
1/10–20. Staining for both CK7 and CK20 has been reported in
the literature for some tumours (Loy and Calaluce, 1994). One
of the adenocarcinomas that has been reported to be positive for
both CK7 and CK20 expression is mucinous bronchioloalveolar
adenocarcinoma of the lung. Goldstein and Thomas (2001) evalu-
ated the expression of CK7 and CK20 in 14 cases of mucinous
bronchioloalveolar adenocarcinomas (BAC) and 11 cases of muci-
nous colon adenocarcinomas. Eleven of the 14 (79%) mucinous
BACs stained positive for CK20, while all 14 (100%) stained posi-
tive for CK7. All cases of mucinous colon adenocarcinoma showed
staining for CK20, while only one out of 11 (9%) was positive for
CK7 (ref). Therefore, both CK7 and CK20 staining of lung lesions
should be obtained and can help to differentiate between a primary
lung vs metastatic colon adenocarcinoma. In difﬁcult cases, staining
for thyroid transcription factor and villin can be helpful in differ-
entiating mucinous BACs from mucinous colon adenocarcinomas
(Goldstein and Thomas, 2001).
The causes for false negative cytokeratin staining include
tumours that express low levels of CK7 or CK20, sampling error
in tumours that are focally positive, and poorly differentiated or
necrotic tissue that may stain poorly for cytokeratin. In our series,
one case of lung lesion in a patient with metastatic colon carcino-
ma did not show staining with either CK7 or CK20. We reviewed
the staining pattern of the primary colon cancer in this patient. It
showed focal staining for CK20 (5–25% of the cells), and was
negative for CK7. Thus, in this case, sampling error could have
accounted for the lack of CK20 staining observed for the lung
lesion.
In conclusion, we observed characteristic cytokeratin staining
patterns for both primary and metastatic lung and colorectal
adenocarcinoma in a series of 102 tumour samples. The CK7/
CK20 pattern was able to identify lung vs colorectal adenocarcino-
ma in 95% of the cases analysed. In the correct clinical setting,
cytokeratin staining is a cost effective screening tool to help in
the diagnostic differentiation of metastatic lesions from these two
common primary sites.
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